Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
Year: 2021
Type: article
Abstract: The purpose was to describe first and subsequent relapses in patients from the OS2006/Sarcome-09 trial, to help future trial design. We prospectively collected and analysed relapse data of all French patients included in the OS2006/Sarcome-09 trial, who had achieved a first complete remission. 157 patients experienced a first relapse. The median interval from diagnosis to relapse was 1.7 year (range 0.5-7.6). The first relapse was metastatic in 83% of patients, and disease was not measurable according to RECIST 1.1 criteria in 23%. Treatment consisted in systemic therapy (74%) and surgical resection (68%). A quarter of the patients were accrued in a phase-II clinical trial. A second complete remission was obtained for 79 patients. Most of them had undergone surgery (76/79). The 3-year progression-free and overall survival rates were 21% and 37%, respectively. In patients who achieved CR2, the 3y-PFS and OS rates were 39% and 62% respectively. Individual correlation between subsequent PFS durations was poor. For osteosarcoma relapses, we recommend randomised phase-II trials, open to patients from all age categories (children, adolescents, adults), not limited to patients with measurable disease (but stratified according to disease status), with PFS as primary endpoint, response rate and surgical CR as secondary endpoints.
Source: Cancers
Authors: Eric Thebault(Investigation, Resources, Writing – original draft, Writing – review & editing), Sophie Piperno-Neumann(Conceptualization), Diep Tran(Data curation), Hélène Pacquement(Data curation, Validation), Perrine Marec-Berard(Data curation), Cyril Lervat(Data curation), Marie-Pierre Castex(Data curation), Morgane Cleirec, Emmanuelle Bompas(Data curation), Jean-Pierre Vannier(Data curation), Dominique Plantaz(Data curation), Laure Saumet(Data curation), Cecile Verite(Data curation), Olivier Collard(Data curation), Claire Pluchart(Data curation), Claire Briandet(Data curation), Laure Monard(Data curation), Laurence Brugieres(Conceptualization, Funding acquisition, Methodology, Project administration, Validation), Marie-Cécile Le Deley(Formal analysis, Methodology, Software, Visualization, Writing – review & editing), Nathalie Gaspar(Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Validation, Visualization, Writing – review & editing)
Institutions: Université Paris-Saclay, Institut Gustave Roussy, Institut Curie, Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Oscar Lambret, Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Nantes, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Montpellier, Hôpital Pellegrin, Institute Cancer De La Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Reims, CHU Dijon Bourgogne, UniCancer Group
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,376
Funder: Chugai Pharmaceutical
OpenAlex ID: W3143999709
